0 395

Cited 285 times in

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

DC Field Value Language
dc.contributor.author라선영-
dc.date.accessioned2016-02-04T11:58:39Z-
dc.date.available2016-02-04T11:58:39Z-
dc.date.issued2015-
dc.identifier.issn1470-2045-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/141618-
dc.description.abstractBACKGROUND: Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We sought to validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in patients with metastatic renal cell carcinoma receiving next-line targeted therapy after progression on first-line targeted therapy. METHODS: In this population-based study, we analysed patients who received second-line targeted therapy for metastatic renal cell carcinoma at 19 centres in Canada, USA, Greece, Japan, Singapore, South Korea, and Denmark. The primary endpoint was overall survival since the initiation of second-line therapy. We compared the prognostic performance of the IMDC model with the three-factor MSKCC model used for previously treated patients for overall survival since the start of second-line targeted therapy. FINDINGS: Between Jan 1, 2005, and Nov 30, 2012, we included 1021 patients treated with second-line targeted therapy. Median overall survival since the start of second-line targeted therapy was 12·5 months (95% CI 11·3-14·3). Five of six predefined factors in the IMDC model (anaemia, thrombocytosis, neutrophilia, Karnofsky performance status [KPS] <80, and <1 year from diagnosis to first-line targeted therapy) were independent predictors of poor overall survival on multivariable analysis. The concordance index using all six prognostic factors (ie, also including hypercalcaemia) was 0·70 (95% CI 0·67-0·72) with the IMDC model and was 0·66 (95% CI 0·64-0·68) with the three-factor MSKCC model. When patients were divided into three risk categories using IMDC criteria, median overall survival was 35·3 months (95% CI 28·3-47·8) in the favourable risk group (n=76), 16·6 months (14·9-17·9) in the intermediate risk group (n=529), and 5·4 months (4·7-6·8) in the poor risk group (n=261). INTERPRETATION: The IMDC prognostic model can be applied to patients previously treated with targeted therapy, in addition to previously validated populations in first-line targeted therapy. The IMDC prognostic model in the second-line targeted therapy setting has an improved prognostic performance and is applicable to a more contemporary patient cohort than that of the three-factor MSKCC model. FUNDING: DF/HCC Kidney Cancer SPORE P50 CA101942-01, Kidney Cancer Research Network of Canada, Canadian Institute for Health Research, Trust Family, Loker Pinard, Michael Brigham, and Gerald DeWulf.-
dc.description.statementOfResponsibilityopen-
dc.format.extent293~300-
dc.relation.isPartOfLANCET ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAsia-
dc.subject.MESHCanada-
dc.subject.MESHCarcinoma, Renal Cell/drug therapy*-
dc.subject.MESHCarcinoma, Renal Cell/mortality-
dc.subject.MESHCarcinoma, Renal Cell/secondary-
dc.subject.MESHChi-Square Distribution-
dc.subject.MESHDatabases, Factual-
dc.subject.MESHDecision Support Techniques*-
dc.subject.MESHEurope-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHKidney Neoplasms/drug therapy*-
dc.subject.MESHKidney Neoplasms/mortality-
dc.subject.MESHKidney Neoplasms/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMolecular Targeted Therapy*/adverse effects-
dc.subject.MESHMolecular Targeted Therapy*/mortality-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHPatient Selection-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Assessment-
dc.subject.MESHRisk Factors-
dc.subject.MESHSalvage Therapy*/adverse effects-
dc.subject.MESHSalvage Therapy*/mortality-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHUnited States-
dc.titleThe International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorJenny J Ko-
dc.contributor.googleauthorWanling Xie-
dc.contributor.googleauthorNils Kroeger-
dc.contributor.googleauthorJae-lyun Lee-
dc.contributor.googleauthorBrian I Rini-
dc.contributor.googleauthorJennifer J Knox-
dc.contributor.googleauthorGeorg A Bjarnason-
dc.contributor.googleauthorSandy Srinivas-
dc.contributor.googleauthorSumanta K Pal-
dc.contributor.googleauthorTakeshi Yuasa-
dc.contributor.googleauthorMartin Smoragiewicz-
dc.contributor.googleauthorFrede Donskov-
dc.contributor.googleauthorRavindran Kanesvaran-
dc.contributor.googleauthorLori Wood-
dc.contributor.googleauthorD Scott Ernst-
dc.contributor.googleauthorNeeraj Agarwal-
dc.contributor.googleauthorUlka N Vaishampayan-
dc.contributor.googleauthorSun-young Rha-
dc.contributor.googleauthorToni K Choueiri-
dc.contributor.googleauthorDaniel Y C Heng-
dc.identifier.doi10.1016/S1470-2045(14)71222-7-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ02154-
dc.identifier.eissn1474-5488-
dc.identifier.pmid25681967-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S1470204514712227-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsnot free-
dc.citation.volume16-
dc.citation.number3-
dc.citation.startPage293-
dc.citation.endPage300-
dc.identifier.bibliographicCitationLANCET ONCOLOGY, Vol.16(3) : 293-300, 2015-
dc.identifier.rimsid30768-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.